Studies related to Immunity and Feverfew

Feverfew In Rheumatoid Arthritis: A Double Blind, Placebo Controlled Study

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 40
Gender Both Genders
Age Range 45-64
Notes for this study:
Oral feverfew at 70-86mg failed to be significantly different than placebo on parameters of rheumatoid arthritis in older female patients. Immunoglobulins A, G, and M were unaffected by treatment